Citius Pharmaceuticals (CTXR) Operating Leases (2019 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Operating Leases came in at $636667.0 in Q1 2026, down 19.07% YoY from $786697.0 in Q1 2025, and down 6.6% on a QoQ basis from $681640.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Operating Leases (2019 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 8 years of Operating Leases data on file, last reported at $636667.0 in Q1 2026.
- Quarterly Operating Leases fell 19.07% year-over-year to $636667.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636667.0 (down 19.07% YoY) and the FY2025 annual result came in at $724925.0, up 3300.53% from the prior year.
- Operating Leases slipped to $636667.0 in Q1 2026, from $681640.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $786697.0 in Q1 2025 to a low of $21318.0 in Q3 2024.
- A 5-year average of $453687.9 and a median of $454907.0 in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2024 — Operating Leases tumbled 91.89% — and 2025, when it jumped 3300.53%.
- Tracing CTXR's Operating Leases over 5 years: stood at $428568.0 in 2022, then increased by 0.0% to $428569.0 in 2023, then plunged by 95.03% to $21318.0 in 2024, then jumped by 3097.49% to $681640.0 in 2025, then decreased by 6.6% to $636667.0 in 2026.
- The last three Operating Leases figures came in at $636667.0 (Q1 2026), $681640.0 (Q4 2025), and $724925.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Citius Pharmaceuticals | 15.88 Mn | 15.88 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636,667.00 |
| Dec 31, 2025 | 681,640.00 |
| Sep 30, 2025 | 724,925.00 |
| Jun 30, 2025 | 766,957.00 |
| Mar 31, 2025 | 786,697.00 |
| Sep 30, 2024 | 21,318.00 |
| Jun 30, 2024 | 84,430.00 |
| Mar 31, 2024 | 145,098.00 |
| Dec 31, 2023 | 428,569.00 |
| Sep 30, 2023 | 262,865.00 |
| Jun 30, 2023 | 320,011.00 |
| Mar 31, 2023 | 374,831.00 |
| Dec 31, 2022 | 428,568.00 |
| Sep 30, 2022 | 481,245.00 |
| Jun 30, 2022 | 532,883.00 |
| Mar 31, 2022 | 582,302.00 |
| Dec 31, 2021 | 630,745.00 |
| Sep 30, 2021 | 678,234.00 |
| Jun 30, 2021 | 897,325.00 |
| Mar 31, 2021 | 769,218.00 |